These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30407912)

  • 1. Early adiposity rebound in patients with Prader-Willi syndrome.
    Oto Y; Murakami N; Matsubara K; Ogata H; Ihara H; Matsubara T; Nagai T
    J Pediatr Endocrinol Metab; 2018 Dec; 31(12):1311-1314. PubMed ID: 30407912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.
    Oto Y; Tanaka Y; Abe Y; Obata K; Tsuchiya T; Yoshino A; Murakami N; Nagai T
    Am J Med Genet A; 2014 Mar; 164A(3):671-5. PubMed ID: 24443368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome.
    Angulo M; Castro-Magana M; Mazur B; Canas JA; Vitollo PM; Sarrantonio M
    J Pediatr Endocrinol Metab; 1996; 9(3):393-400. PubMed ID: 8887149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the value of growth hormone therapy in Prader Willi syndrome?
    Bridges N
    Arch Dis Child; 2014 Feb; 99(2):166-70. PubMed ID: 24162007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
    J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of growth hormone treatment on height, weight, and obesity in Taiwanese patients with Prader-Willi syndrome.
    Lin HY; Lin SP; Tsai LP; Chao MC; Chen MR; Chuang CK; Huang CY; Tsai FJ; Chou IC; Chiu PC; Huang CH; Yen JL; Lin JL; Kuo PL
    J Chin Med Assoc; 2008 Jun; 71(6):305-9. PubMed ID: 18567561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
    Allen DB; Carrel AL
    J Pediatr Endocrinol Metab; 2004 Sep; 17 Suppl 4():1297-306. PubMed ID: 15506076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone secretion decreases with age in paediatric Prader-Willi syndrome.
    Cohen M; Harrington J; Narang I; Hamilton J
    Clin Endocrinol (Oxf); 2015 Aug; 83(2):212-5. PubMed ID: 25495188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of growth hormone therapy on cardiac dimensions in children and adolescents with Prader-Willi syndrome.
    Hauffa BP; Knaup K; Lehmann N; Neudorf U; Nagel B
    Horm Res Paediatr; 2011; 75(1):56-62. PubMed ID: 20924154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE; Carrel AL; Whitman BY; Allen DB
    J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Genotype and Previous GH Treatment on Adiposity in Adults With Prader-Willi Syndrome.
    Coupaye M; Tauber M; Cuisset L; Laurier V; Bieth E; Lacorte JM; Oppert JM; Clément K; Poitou C
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4895-4903. PubMed ID: 27662437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome.
    Dağdeviren Çakır A; Baş F; Akın O; Şıklar Z; Özcabı B; Berberoğlu M; Kardelen AD; Bayramoğlu E; Poyrazoğlu Ş; Aydın M; Törel Ergür A; Gökşen D; Bolu S; Aycan Z; Tüysüz B; Ercan O; Evliyaoğlu O
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):308-319. PubMed ID: 33565750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome.
    Lafortuna CL; Minocci A; Capodaglio P; Gondoni LA; Sartorio A; Vismara L; Rizzo G; Grugni G
    J Clin Endocrinol Metab; 2014 May; 99(5):1816-24. PubMed ID: 24471571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of adiponectin receptor expression with cytokines and insulin sensitivity in growth hormone (GH)-treated children with Prader-Willi syndrome and in non-GH-treated obese children.
    Sohn YB; Kwak MJ; Kim SJ; Park SW; Kim CH; Kim MY; Kwon EK; Paik KH; Jin DK
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1371-7. PubMed ID: 20061428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome.
    Höybye C; Thorén M; Böhm B
    J Intellect Disabil Res; 2005 Apr; 49(Pt 4):245-52. PubMed ID: 15816811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
    Corripio R; Tubau C; Calvo L; Brun C; Capdevila N; Larramona H; Gabau E
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):879-884. PubMed ID: 31271556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy.
    Zipf WB
    Acta Paediatr Suppl; 1999 Dec; 88(433):115-7. PubMed ID: 10626560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
    Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC
    Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.